MEDICINOVA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
MEDICINOVA, INC. (MNOV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $2.84 per share for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2025-08-14
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.94, a 22.50% increase year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.40, a 6.67% increase year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.25, a 61.99% decline year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.92, a 14.94% decline year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $4.64, a 41.90% increase from fiscal 2023.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $3.27, a 44.10% decline from fiscal 2022.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $5.85, a 13.59% decline from fiscal 2021.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $6.77, a 22.45% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-06-30 | $2.84 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $2.94 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $4.64 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $2.51 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $2.15 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $2.40 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $3.27 10-K · filed 2025-02-19 | |||
| 2023-09-30 | $3.99 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.99 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $2.25 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $5.85 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $5.85 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $5.88 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $5.92 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $6.77 10-K/A · filed 2023-03-28 | |||
| 2021-09-30 | $6.71 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $6.96 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $6.96 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $8.73 10-K · filed 2022-02-16 | |||
| 2020-09-30 | $8.92 10-Q · filed 2020-10-26 | |||
| 2020-06-30 | $9.17 10-Q · filed 2020-07-28 | |||
| 2020-03-31 | $9.16 10-Q · filed 2020-04-23 | |||
| 2019-12-31 | $8.84 10-K · filed 2021-02-19 | |||
| 2019-09-30 | $8.84 10-Q · filed 2019-10-24 | |||
| 2019-06-30 | $9.67 10-Q · filed 2019-07-25 | |||
| 2019-03-31 | $9.67 10-Q · filed 2019-04-25 | |||
| 2018-12-31 | $4.52 10-K · filed 2020-02-13 | |||
| 2018-09-30 | $4.52 10-Q · filed 2018-10-25 | |||
| 2018-06-30 | $4.52 10-Q · filed 2018-07-23 | |||
| 2017-12-31 | $7.76 10-K · filed 2019-02-13 | |||
| 2017-09-30 | $7.76 10-Q · filed 2017-10-23 | |||
| 2017-06-30 | $7.96 10-Q · filed 2017-07-26 | |||
| 2016-12-31 | $11.27 10-K · filed 2019-02-13 | |||
| 2016-09-30 | $16.47 10-Q · filed 2016-10-25 | |||
| 2016-06-30 | $12.45 10-Q · filed 2016-07-26 | |||
| 2016-03-31 | $12.41 10-Q · filed 2016-04-27 | |||
| 2015-12-31 | $9.27 10-K · filed 2018-02-13 | |||
| 2015-09-30 | $9.27 10-Q · filed 2015-10-29 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $3.30 10-K · filed 2017-02-14 | |||
| 2014-09-30 | $3.30 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $3.18 10-Q · filed 2014-08-13 | |||
| 2014-03-31 | $2.81 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | $3.29 10-K · filed 2014-03-27 | |||
| 2013-09-30 | $2.99 10-Q · filed 2013-11-07 | |||
| 2013-06-30 | $2.28 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $2.24 10-Q · filed 2013-05-08 | |||
| 2012-12-31 | $4.57 10-K · filed 2013-03-28 | |||
| 2012-09-30 | $4.57 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $2.68 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |